EMCORE Corporation (NASDAQ: EMKR) announced today that it has signed an Agreement and Plan of Merger with Velocity One Holdings, LP, Aerosphere Power Inc., and Velocity Merger Sub, Inc.

At the same time, AstraZeneca also launched its latest triple therapy, Breztri Aerosphere® to cater to the unmet needs of patients living with chronic obstructive pulmonary disease (COPD).

Bevespi Aerosphere is a twice-daily bronchodilator combining glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta-2 agonist (LABA).

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...